MedTrace Logo

Study of Aolanti Weikang Tablets in Healthy Volunteers

NCT03358485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses escalation of Aolanti Weikang tablets to determine the MTD in healthy volunteers

Conditions

  • Functional Dyspepsia

Interventions

DRUG

Aolanti Weikang tablets

Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Xudong Tang · Xiyuan Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-14
Primary Completion
2018-04-21
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358485 on ClinicalTrials.gov